Technical Analysis for CRY - CryoLife, Inc.

Grade Last Price % Change Price Change
grade C 21.85 1.16% 0.25
CRY closed up 1.16 percent on Friday, September 22, 2017, on 55 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical CRY trend table...

Date Alert Name Type % Chg
Sep 22 Bullish Engulfing Bullish 0.00%
Sep 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Sep 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 21 NR7 Range Contraction 1.16%
Sep 21 Narrow Range Bar Range Contraction 1.16%

Older signals for CRY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

CryoLife, Inc. preserves and distributes human tissues for transplantation in the United States and internationally. The company also develops, manufactures, and commercializes medical devices for cardiac and vascular applications. It distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using CryoLife's proprietary SynerGraft technology; and vascular tissues comprising CryoVein and CryoArtery to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company also distributes surgical sealants and hemostats, including BioGlue Surgical Adhesive, an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels, as well as in repair of cardiac, vascular, pulmonary, and additional soft tissues. In addition, its surgical sealants and hemostats comprise BioFoam Surgical Matrix for use as an adjunct in the sealing of abdominal parenchymal tissues, when cessation of bleeding by ligature or conventional methods is ineffective or impractical; PerClot, an absorbable powdered hemostat agent used in surgery; and revascularization technologies, which include transmyocardial revascularization system for treating patients with stable angina that is not responsive to conventional therapy. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization. The company, through its subsidiary, Hemosphere, Inc., markets HeRO Graft, a solution for end-stage renal disease in certain hemodialysis patients. CryoLife distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Is CRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 23.35
52 Week Low 14.02
Average Volume 163,184
200-Day Moving Average 18.5464
50-Day Moving Average 20.0335
20-Day Moving Average 21.5913
10-Day Moving Average 22.3325
Average True Range 0.6242
ADX 40.53
+DI 26.35
-DI: 15.35
Chandelier Exit (Long, 3 ATRs) 21.4774
Chandelier Exit (Short, 3 ATRs) 20.5226
Upper Bollinger Band 23.8169
Lower Bollinger Band 19.3657
Percent B (%b) 0.56
Bandwidth 0.206157
MACD Line 0.6611
MACD Signal Line 0.7764
MACD Histogram -0.1153